Impact of efalizumab on patient-reported outcomes in high-need psoriasis patients: results of the international, randomized, placebo-controlled Phase III Clinical Experience Acquired with Raptiva (CLEAR) trial [NCT00256139]
Identifieur interne : 00A167 ( Main/Exploration ); précédent : 00A166; suivant : 00A168Impact of efalizumab on patient-reported outcomes in high-need psoriasis patients: results of the international, randomized, placebo-controlled Phase III Clinical Experience Acquired with Raptiva (CLEAR) trial [NCT00256139]
Auteurs : Jean-Paul Ortonne [France] ; Neil Shear [Canada] ; Stephen Shumack [Australie] ; Eric Henninger [Suisse]Source :
- BMC Dermatology [ 1471-5945 ] ; 2005.
Abstract
Chronic psoriasis can negatively affect patients' lives. Assessing the impact of treatment on different aspects of a patient's health-related quality of life (HRQOL) is therefore important and relevant in trials of anti-psoriasis agents. The recombinant humanized IgG1 monoclonal antibody efalizumab targets multiple T-cell-dependent steps in the immunopathogenesis of psoriasis. Efalizumab has demonstrated safety and efficacy in several clinical trials, and improves patients' quality of life. Objective: To evaluate the impact of efalizumab on HRQOL and other patient-reported outcomes in patients with moderate to severe plaque psoriasis, including a large cohort of High-Need patients for whom at least 2 other systemic therapies were unsuitable because of lack of efficacy, intolerance, or contraindication.
A total of 793 patients were randomized in a 2:1 ratio to receive efalizumab 1 mg/kg/wk (n = 529) or placebo (n = 264) for 12 weeks. The study population included 526 High-Need patients (342 efalizumab, 184 placebo). The treatment was evaluated by patients using the HRQOL assessment tools Short Form-36 (SF-36) and Dermatology Life Quality Index (DLQI). Other patient-reported assessments included the Psoriasis Symptom Assessment (PSA), a visual analog scale (VAS) for itching, and the Patient's Global Psoriasis Assessment (PGPA).
Efalizumab was associated with improvements at Week 12 from baseline in patient-reported outcomes, both in the total study population and in the High-Need cohort. Among all efalizumab-treated patients, the DLQI improved by 5.7 points from baseline to Week 12, relative to an improvement of 2.3 points for placebo patients (
A 12-week course of efalizumab improved HRQOL and other patient-reported outcomes in patients with moderate to severe plaque psoriasis. The benefits of efalizumab therapy in High-Need patients were similar to those observed in the total study population, indicating that the beneficial impact of efalizumab on QOL is consistent regardless of disease severity, prior therapy, or contraindications to previous therapies.
Url:
DOI: 10.1186/1471-5945-5-13
PubMed: 16359548
PubMed Central: 1343580
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Pmc, to step Corpus: 001082
- to stream Pmc, to step Curation: 000F43
- to stream Pmc, to step Checkpoint: 002C52
- to stream Ncbi, to step Merge: 000165
- to stream Ncbi, to step Curation: 000165
- to stream Ncbi, to step Checkpoint: 000165
- to stream Main, to step Merge: 00AD26
- to stream Main, to step Curation: 00A167
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Impact of efalizumab on patient-reported outcomes in high-need psoriasis patients: results of the international, randomized, placebo-controlled Phase III Clinical Experience Acquired with Raptiva (CLEAR) trial [NCT00256139]</title>
<author><name sortKey="Ortonne, Jean Paul" sort="Ortonne, Jean Paul" uniqKey="Ortonne J" first="Jean-Paul" last="Ortonne">Jean-Paul Ortonne</name>
<affiliation wicri:level="3"><nlm:aff id="I1">Hôpital L'Archet, Nice, France</nlm:aff>
<country xml:lang="fr">France</country>
<wicri:regionArea>Hôpital L'Archet, Nice</wicri:regionArea>
<placeName><region type="region">Provence-Alpes-Côte d'Azur</region>
<region type="old region">Provence-Alpes-Côte d'Azur</region>
<settlement type="city">Nice</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Shear, Neil" sort="Shear, Neil" uniqKey="Shear N" first="Neil" last="Shear">Neil Shear</name>
<affiliation wicri:level="1"><nlm:aff id="I2">Ventana Clinical Research, Toronto, Ontario, Canada</nlm:aff>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Ventana Clinical Research, Toronto, Ontario</wicri:regionArea>
<wicri:noRegion>Ontario</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Shumack, Stephen" sort="Shumack, Stephen" uniqKey="Shumack S" first="Stephen" last="Shumack">Stephen Shumack</name>
<affiliation wicri:level="1"><nlm:aff id="I3">St George Dermatology, Kogarah, Australia</nlm:aff>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>St George Dermatology, Kogarah</wicri:regionArea>
<wicri:noRegion>Kogarah</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Henninger, Eric" sort="Henninger, Eric" uniqKey="Henninger E" first="Eric" last="Henninger">Eric Henninger</name>
<affiliation wicri:level="1"><nlm:aff id="I4">Serono International S.A., Geneva, Switzerland</nlm:aff>
<country xml:lang="fr">Suisse</country>
<wicri:regionArea>Serono International S.A., Geneva</wicri:regionArea>
<wicri:noRegion>Geneva</wicri:noRegion>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PMC</idno>
<idno type="pmid">16359548</idno>
<idno type="pmc">1343580</idno>
<idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1343580</idno>
<idno type="RBID">PMC:1343580</idno>
<idno type="doi">10.1186/1471-5945-5-13</idno>
<date when="2005">2005</date>
<idno type="wicri:Area/Pmc/Corpus">001082</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">001082</idno>
<idno type="wicri:Area/Pmc/Curation">000F43</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">000F43</idno>
<idno type="wicri:Area/Pmc/Checkpoint">002C52</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Checkpoint">002C52</idno>
<idno type="wicri:Area/Ncbi/Merge">000165</idno>
<idno type="wicri:Area/Ncbi/Curation">000165</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">000165</idno>
<idno type="wicri:Area/Main/Merge">00AD26</idno>
<idno type="wicri:Area/Main/Curation">00A167</idno>
<idno type="wicri:Area/Main/Exploration">00A167</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Impact of efalizumab on patient-reported outcomes in high-need psoriasis patients: results of the international, randomized, placebo-controlled Phase III Clinical Experience Acquired with Raptiva (CLEAR) trial [NCT00256139]</title>
<author><name sortKey="Ortonne, Jean Paul" sort="Ortonne, Jean Paul" uniqKey="Ortonne J" first="Jean-Paul" last="Ortonne">Jean-Paul Ortonne</name>
<affiliation wicri:level="3"><nlm:aff id="I1">Hôpital L'Archet, Nice, France</nlm:aff>
<country xml:lang="fr">France</country>
<wicri:regionArea>Hôpital L'Archet, Nice</wicri:regionArea>
<placeName><region type="region">Provence-Alpes-Côte d'Azur</region>
<region type="old region">Provence-Alpes-Côte d'Azur</region>
<settlement type="city">Nice</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Shear, Neil" sort="Shear, Neil" uniqKey="Shear N" first="Neil" last="Shear">Neil Shear</name>
<affiliation wicri:level="1"><nlm:aff id="I2">Ventana Clinical Research, Toronto, Ontario, Canada</nlm:aff>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Ventana Clinical Research, Toronto, Ontario</wicri:regionArea>
<wicri:noRegion>Ontario</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Shumack, Stephen" sort="Shumack, Stephen" uniqKey="Shumack S" first="Stephen" last="Shumack">Stephen Shumack</name>
<affiliation wicri:level="1"><nlm:aff id="I3">St George Dermatology, Kogarah, Australia</nlm:aff>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>St George Dermatology, Kogarah</wicri:regionArea>
<wicri:noRegion>Kogarah</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Henninger, Eric" sort="Henninger, Eric" uniqKey="Henninger E" first="Eric" last="Henninger">Eric Henninger</name>
<affiliation wicri:level="1"><nlm:aff id="I4">Serono International S.A., Geneva, Switzerland</nlm:aff>
<country xml:lang="fr">Suisse</country>
<wicri:regionArea>Serono International S.A., Geneva</wicri:regionArea>
<wicri:noRegion>Geneva</wicri:noRegion>
</affiliation>
</author>
</analytic>
<series><title level="j">BMC Dermatology</title>
<idno type="eISSN">1471-5945</idno>
<imprint><date when="2005">2005</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass></textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en"><sec><title>Background</title>
<p>Chronic psoriasis can negatively affect patients' lives. Assessing the impact of treatment on different aspects of a patient's health-related quality of life (HRQOL) is therefore important and relevant in trials of anti-psoriasis agents. The recombinant humanized IgG<sub>1 </sub>
monoclonal antibody efalizumab targets multiple T-cell-dependent steps in the immunopathogenesis of psoriasis. Efalizumab has demonstrated safety and efficacy in several clinical trials, and improves patients' quality of life. Objective: To evaluate the impact of efalizumab on HRQOL and other patient-reported outcomes in patients with moderate to severe plaque psoriasis, including a large cohort of High-Need patients for whom at least 2 other systemic therapies were unsuitable because of lack of efficacy, intolerance, or contraindication.</p>
</sec>
<sec sec-type="methods"><title>Methods</title>
<p>A total of 793 patients were randomized in a 2:1 ratio to receive efalizumab 1 mg/kg/wk (n = 529) or placebo (n = 264) for 12 weeks. The study population included 526 High-Need patients (342 efalizumab, 184 placebo). The treatment was evaluated by patients using the HRQOL assessment tools Short Form-36 (SF-36) and Dermatology Life Quality Index (DLQI). Other patient-reported assessments included the Psoriasis Symptom Assessment (PSA), a visual analog scale (VAS) for itching, and the Patient's Global Psoriasis Assessment (PGPA).</p>
</sec>
<sec><title>Results</title>
<p>Efalizumab was associated with improvements at Week 12 from baseline in patient-reported outcomes, both in the total study population and in the High-Need cohort. Among all efalizumab-treated patients, the DLQI improved by 5.7 points from baseline to Week 12, relative to an improvement of 2.3 points for placebo patients (<italic>P </italic>
< .001). Corresponding improvements in DLQI in the High-Need cohort were 5.4 points for efalizumab compared to 2.3 for placebo (<italic>P </italic>
< .001). Improvements from baseline on the SF-36, PSA, PGPA, and itching VAS at Week 12 were also significantly greater in efalizumab-treated patients than for placebo.</p>
</sec>
<sec><title>Conclusion</title>
<p>A 12-week course of efalizumab improved HRQOL and other patient-reported outcomes in patients with moderate to severe plaque psoriasis. The benefits of efalizumab therapy in High-Need patients were similar to those observed in the total study population, indicating that the beneficial impact of efalizumab on QOL is consistent regardless of disease severity, prior therapy, or contraindications to previous therapies.</p>
</sec>
</div>
</front>
<back><div1 type="bibliography"><listBibl><biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
<biblStruct></biblStruct>
</listBibl>
</div1>
</back>
</TEI>
<affiliations><list><country><li>Australie</li>
<li>Canada</li>
<li>France</li>
<li>Suisse</li>
</country>
<region><li>Provence-Alpes-Côte d'Azur</li>
</region>
<settlement><li>Nice</li>
</settlement>
</list>
<tree><country name="France"><region name="Provence-Alpes-Côte d'Azur"><name sortKey="Ortonne, Jean Paul" sort="Ortonne, Jean Paul" uniqKey="Ortonne J" first="Jean-Paul" last="Ortonne">Jean-Paul Ortonne</name>
</region>
</country>
<country name="Canada"><noRegion><name sortKey="Shear, Neil" sort="Shear, Neil" uniqKey="Shear N" first="Neil" last="Shear">Neil Shear</name>
</noRegion>
</country>
<country name="Australie"><noRegion><name sortKey="Shumack, Stephen" sort="Shumack, Stephen" uniqKey="Shumack S" first="Stephen" last="Shumack">Stephen Shumack</name>
</noRegion>
</country>
<country name="Suisse"><noRegion><name sortKey="Henninger, Eric" sort="Henninger, Eric" uniqKey="Henninger E" first="Eric" last="Henninger">Eric Henninger</name>
</noRegion>
</country>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 00A167 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 00A167 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Asie |area= AustralieFrV1 |flux= Main |étape= Exploration |type= RBID |clé= PMC:1343580 |texte= Impact of efalizumab on patient-reported outcomes in high-need psoriasis patients: results of the international, randomized, placebo-controlled Phase III Clinical Experience Acquired with Raptiva (CLEAR) trial [NCT00256139] }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:16359548" \ | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \ | NlmPubMed2Wicri -a AustralieFrV1
This area was generated with Dilib version V0.6.33. |